Marc A. Unger

Marc A. Unger is the current Chief Scientific Officer at Elegen. Prior to this, they were the Chief Executive Officer at Hyalos Therapeutics from December 2016 to August 2019. Marc has also served as the Executive Vice President of Research and Development and Marketing at Fluidigm Corporation from September 2012 to December 2016.

Marc founded Hyalos with Professor Paul Bollyky and Nadine Nagy of Stanford University, based on first-in-class oral drugs which induce regulatory T cells by inhibition of hyaluronic acid. Treg induction has promise against multiple autoimmune diseases, including Type 1 Diabetes, rheumatoid arthritis, and multiple sclerosis.

At Fluidigm Corporation, Marc was a member of the Executive Staff and they drove R&D Portfolio Management and New Product Commercialization processes. Marc also stabilized, restructured, built out, and managed the Marketing organization. In addition, they managed both Marketing and genomics R&D and recruited high-caliber, experienced senior VPs for Marketing and R&D.

Marc A. Unger graduated from Union College with a B.S. in Chemistry. Marc then went on to get their PhD in Chemistry from Caltech. After that, they attended the Stanford Executive Institute at Stanford University.

They are on a team with Jodie Bowen - Corporate Controller, Dan La Caze - Chief Business Officer, and Mark Lasinski - SVP, Sales. Marc A. Unger reports to Matt Hill, Founder & CEO.